Optimal Perfusion Targets in Cardiogenic Shock
- PMID: 38939320
- PMCID: PMC11198174
- DOI: 10.1016/j.jacadv.2022.100034
Optimal Perfusion Targets in Cardiogenic Shock
Abstract
Cardiology shock is a syndrome of low cardiac output resulting in end-organ dysfunction. Few interventions have demonstrated meaningful clinical benefit, and cardiogenic shock continues to carry significant morbidity with mortality rates that have plateaued at upwards of 40% over the past decade. Clinicians must rely on clinical, biochemical, and hemodynamic parameters to guide resuscitation. Several features, including physical examination, renal function, serum lactate metabolism, venous oxygen saturation, and hemodynamic markers of right ventricular function, may be useful both as prognostic markers and to guide therapy. This article aims to review these targets, their utility in the care of patients with cardiology shock, and their association with outcomes.
Keywords: cardiogenic shock; lactate; mean arterial pressure; resuscitation; target.
© 2022 The Authors.
Conflict of interest statement
Dr Brodie has received research support from ALung Technologies; has been on the medical advisory boards for Abiomed, Xenios, Medtronic, Inspira, and Cellenkos; is the President-elect of the Extracorporeal Life Support Organization (ELSO); and is the Chair of the Executive Committee of the International ECMO Network (ECMONet). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures


References
-
- Hochman J.S., Sleeper L.A., Webb J.G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 1999;341(9):625–634. - PubMed
-
- De Backer D., Biston P., Devriendt J., et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–789. - PubMed
-
- Levy B., Clere-Jehl R., Legras A., et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2018;72(2):173–182. - PubMed
-
- TRIUMPH Investigators. Alexander J.H., Reynolds H.R., et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007;297(15):1657–1666. - PubMed
-
- Felker G.M., Benza R.L., Chandler A.B., et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41(6):997–1003. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous